Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905459 · ClinicalTrials.gov registry record
ARDA Software for the Detection of mtmDR
A clinical trial, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 1,012
- Enrollment target
NCT04905459: Completed study, sponsored by Verily Life Sciences.
NCT04905459 is a clinical trial that has completed, run by Verily Life Sciences. The registered enrollment target is 1,012 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04905459 has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 1,012 participants
- Enrollment target
Study Summary
This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.
Interventions
- DIAGNOSTIC_TEST ARDA software application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2022-05-23 |
What the finished NCT04905459 record still lists
NCT04905459 is an observational study that tracks outcomes without assigning an intervention. Its 1,012 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which ARDA software application is the first listed.
NCT04905459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04905459 about?
NCT04905459 is a clinical study titled "ARDA Software for the Detection of mtmDR". This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.
What is the current status of trial NCT04905459?
This trial is currently completed. The enrollment target is 1,012 participants. The study started on 2021-09-30. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT04905459?
The interventions under investigation include: ARDA software application (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04905459?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI